1. Home
  2. CUE vs LSBK Comparison

CUE vs LSBK Comparison

Compare CUE & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • LSBK
  • Stock Information
  • Founded
  • CUE 2014
  • LSBK 1891
  • Country
  • CUE United States
  • LSBK United States
  • Employees
  • CUE N/A
  • LSBK N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • LSBK Savings Institutions
  • Sector
  • CUE Health Care
  • LSBK Finance
  • Exchange
  • CUE Nasdaq
  • LSBK Nasdaq
  • Market Cap
  • CUE 91.9M
  • LSBK 91.1M
  • IPO Year
  • CUE 2018
  • LSBK 2006
  • Fundamental
  • Price
  • CUE $1.33
  • LSBK $15.82
  • Analyst Decision
  • CUE Strong Buy
  • LSBK
  • Analyst Count
  • CUE 5
  • LSBK 0
  • Target Price
  • CUE $5.00
  • LSBK N/A
  • AVG Volume (30 Days)
  • CUE 271.8K
  • LSBK 3.4K
  • Earning Date
  • CUE 03-10-2025
  • LSBK 01-24-2025
  • Dividend Yield
  • CUE N/A
  • LSBK 4.56%
  • EPS Growth
  • CUE N/A
  • LSBK 7.32
  • EPS
  • CUE N/A
  • LSBK 0.88
  • Revenue
  • CUE $9,532,000.00
  • LSBK $25,846,000.00
  • Revenue This Year
  • CUE $73.11
  • LSBK N/A
  • Revenue Next Year
  • CUE $11.02
  • LSBK N/A
  • P/E Ratio
  • CUE N/A
  • LSBK $17.98
  • Revenue Growth
  • CUE 149.53
  • LSBK N/A
  • 52 Week Low
  • CUE $0.45
  • LSBK $10.30
  • 52 Week High
  • CUE $2.37
  • LSBK $15.98
  • Technical
  • Relative Strength Index (RSI)
  • CUE 50.46
  • LSBK 68.62
  • Support Level
  • CUE $1.22
  • LSBK $15.53
  • Resistance Level
  • CUE $1.50
  • LSBK $15.78
  • Average True Range (ATR)
  • CUE 0.12
  • LSBK 0.36
  • MACD
  • CUE -0.02
  • LSBK 0.14
  • Stochastic Oscillator
  • CUE 43.33
  • LSBK 93.89

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

Share on Social Networks: